IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.422
NA - Nord America 2.924
SA - Sud America 1.458
EU - Europa 536
AF - Africa 112
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 9.463
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.056
US - Stati Uniti d'America 2.781
BR - Brasile 1.249
CN - Cina 555
VN - Vietnam 329
HK - Hong Kong 153
IT - Italia 118
GB - Regno Unito 91
AR - Argentina 87
DE - Germania 61
MX - Messico 61
CA - Canada 60
BD - Bangladesh 57
IN - India 53
ZA - Sudafrica 52
EC - Ecuador 44
FR - Francia 34
IQ - Iraq 31
ID - Indonesia 28
PL - Polonia 28
ES - Italia 23
JP - Giappone 21
NL - Olanda 21
RU - Federazione Russa 21
TR - Turchia 21
UA - Ucraina 21
FI - Finlandia 20
SE - Svezia 19
PY - Paraguay 16
MA - Marocco 15
PK - Pakistan 15
CO - Colombia 14
CZ - Repubblica Ceca 14
UY - Uruguay 14
EG - Egitto 13
UZ - Uzbekistan 13
LT - Lituania 12
AE - Emirati Arabi Uniti 10
CL - Cile 10
IE - Irlanda 10
KE - Kenya 9
VE - Venezuela 9
AT - Austria 8
DZ - Algeria 8
SA - Arabia Saudita 8
KR - Corea 7
PE - Perù 7
TN - Tunisia 7
BO - Bolivia 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
JO - Giordania 6
NP - Nepal 6
AZ - Azerbaigian 5
IL - Israele 5
KZ - Kazakistan 5
OM - Oman 5
PS - Palestinian Territory 5
AU - Australia 4
BE - Belgio 4
GR - Grecia 4
TT - Trinidad e Tobago 4
AL - Albania 3
LB - Libano 3
LK - Sri Lanka 3
NG - Nigeria 3
PH - Filippine 3
TH - Thailandia 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
EE - Estonia 2
GY - Guiana 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KW - Kuwait 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GT - Guatemala 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
MM - Myanmar 1
MY - Malesia 1
Totale 9.458
Salva come PNG Salva come JPEG
Città #
Singapore 932
The Dalles 837
Dallas 444
Shanghai 334
Ashburn 277
Beijing 157
Hong Kong 148
Ho Chi Minh City 130
São Paulo 112
Santa Clara 82
Boardman 71
Hanoi 71
Los Angeles 58
New York 48
Rio de Janeiro 43
Seattle 38
Belo Horizonte 35
Johannesburg 31
Chandler 29
Mexico City 27
Brasília 26
Chicago 22
Milan 22
Warsaw 22
Curitiba 21
Tokyo 21
London 20
Phoenix 20
Council Bluffs 19
Helsinki 19
Guayaquil 18
Boston 17
Brooklyn 17
Campinas 17
Dhaka 17
Ribeirão Preto 16
Toronto 16
Atlanta 15
Montreal 15
Porto Alegre 15
Quito 14
San Francisco 13
Stockholm 13
Wilmington 13
Goiânia 12
Montevideo 12
Munich 12
Sorocaba 12
Ankara 11
Cape Town 11
Caxias do Sul 11
Hải Dương 11
Rome 11
Tashkent 11
Asunción 10
Charlotte 10
Dublin 10
Lauterbourg 10
Manchester 10
Recife 10
Reston 10
Aracaju 9
Campo Grande 9
Denver 9
Haiphong 9
New Delhi 9
Santos 9
Amsterdam 8
Baghdad 8
Bauru 8
Brno 8
Joinville 8
Orem 8
Paris 8
Poplar 8
Salvador 8
Santo André 8
Volta Redonda 8
Biên Hòa 7
Cabo Frio 7
Cairo 7
Da Nang 7
Houston 7
Indaiatuba 7
Mumbai 7
Thái Nguyên 7
Amman 6
Assago 6
Can Tho 6
Córdoba 6
Erbil 6
Florianópolis 6
Juiz de Fora 6
Jundiaí 6
Kingston 6
Lawrence 6
Mauá 6
Nairobi 6
Naples 6
Nuremberg 6
Totale 4.798
Salva come PNG Salva come JPEG
Nome #
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 173
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 161
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 124
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 104
Pembrolizumab for locally advanced cervical cancer - Authors' reply 76
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 68
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 67
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 65
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 60
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 57
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 57
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 51
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 51
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 51
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 50
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 46
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 46
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 46
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 45
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 45
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 45
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 42
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 42
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 41
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 41
"Tumori della vulva e della vagina" 40
A critical assessment on the role of sentinel node mapping in endometrial cancer 40
Trabectedin as a chemotherapy option for patients with BRCA deficiency 40
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 39
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 39
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 39
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 39
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 38
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 38
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 38
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 36
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 36
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 36
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 35
Advances in laparoscopic surgery for cervical cancer 35
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 35
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 35
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 34
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 34
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 34
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 34
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 34
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 34
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 34
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 34
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 34
Do you agree with populations that have been defined as 'noncandidates' to receiving platinum? 33
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 33
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 33
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 33
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 33
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity 33
Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study 33
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 33
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 32
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 32
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 32
Uterine serous carcinoma 32
Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers 31
Peritoneal cytology as prognostic factor in cervical cancer 31
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 31
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 31
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 31
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 31
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 31
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer 31
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe 31
Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. 31
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 31
Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction 31
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses 31
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 30
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? 30
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features 30
Management of stage III and IVa uterine cancer 30
Nomogram-based prediction of cervical dysplasia persistence/recurrence 30
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 30
Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer 30
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy 29
Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 29
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 29
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 29
A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLO) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group 28
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study 28
Maternal ultrasound bone density in normal pregnancy 28
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial 28
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 27
Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study 27
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience 27
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 27
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 27
Reply to P.-H. Luo et al 27
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 27
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 27
Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital 27
Totale 4.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.437
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.437
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 7 4 3 6 3 0 3
2021/202219 2 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/20264.555 1.630 779 648 982 378 138 0 0 0 0 0 0
Totale 9.857